Literature DB >> 6605366

Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

W J Koopman, R E Schrohenloher, J C Barton, E C Greenleaf.   

Abstract

Previous studies have indicated that antiidiotypic antibody can modulate expression of idiotype both in vivo and in vitro. Although the precise mechanisms underlying modulation of idiotype expression by antiidiotype remains unclear, a requirement for intact IgG antiidiotypic antibody has been suggested and T cells appear to play a role in some systems. We have studied peripheral blood mononuclear leukocytes (MNL) from a patient with a B cell lymphoma and a circulating IgMK rheumatoid factor (RF) paraprotein in an effort to delineate mechanisms involved in regulation of idiotype expression by antiidiotypic antibody. 1-10% of MNL from this patient could be cytoplasmically stained with specific F(ab')2 antiidiotypic antibody. MNL from the patient spontaneously synthesized IgM RF in culture that possessed the same idiotype as the circulating IgM RF paraprotein. Production of RF by MNL was suppressed by pretreatment with either intact IgG or the F(ab')2 fragments of antiidiotypic antibody (50% inhibitory concentration was 0.2 and 1.1 micrograms/culture, respectively). In contrast, the Fab' fragment of antiidiotypic antibody was not inhibitory (up to 57 micrograms/culture) despite retaining demonstrable antiidiotype activity. Suppression of RF production was not observed over the same concentration range with the IgG or F(ab')2 fractions of a non-cross-reactive antiidiotypic antibody prepared against another monoclonal IgMK RF paraprotein or with IgG or F(ab')2 fractions prepared from normal rabbit serum. Inhibition of RF production by antiidiotypic antibody did not require T cells. Antiidiotypic antibody decreased intracellular and extracellular levels of idiotype indicating diminished synthesis of idiotype by the patient's B cells. Synthesis of IgM RF by MNL obtained from unrelated donors was not suppressed by the antiidiotypic antibody specific for the patient's paraprotein. The results indicate that (a) antiidiotypic antibody is capable of directly suppressing human B cell release of idiotype, (b) the bivalent antigen-binding fragment (F[ab']2) of antiidiotypic antibody is sufficient for mediating such suppression, (c) an intact Fc portion of antiidiotypic antibody enhances suppression of idiotype, and (d) antiidiotypic antibody inhibits idiotype expression by suppressing synthesis of idiotype.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605366      PMCID: PMC370425          DOI: 10.1172/JCI111097

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  ULTRACENTRIFUGE STUDIES WITH ABSORPTION OPTICS. 3. A SPLIT-BEAM PHOTOELECTRIC, SCANNING ABSORPTION SYSTEM.

Authors:  K LAMERS; F PUTNEY; I Z STEINBERG; H K SCHACHMAN
Journal:  Arch Biochem Biophys       Date:  1963-12       Impact factor: 4.013

2.  GROSS CONFORMATION OF RABBIT 7 S GAMMA-IMMUNOGLOBULIN AND ITS PAPAIN-CLEAVED FRAGMENTS.

Authors:  M E NOELKEN; C A NELSON; C E BUCKLEY; C TANFORD
Journal:  J Biol Chem       Date:  1965-01       Impact factor: 5.157

3.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

4.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

5.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

6.  Lymphoid cell responses to bacterial cell wall components: polyclonal and immune responses of murine B cells to Streptococcus mutans carbohydrate antigens.

Authors:  M Torii; J R McGhee; W J Koopman; S Hamada; S M Michalek
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

7.  Cellular localization of rheumatoid factor idiotypes.

Authors:  V R Bonagura; H G Kunkel; B Pernis
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

8.  Tissue origins of human polymeric and monomeric IgA.

Authors:  W H Kutteh; S J Prince; J Mestecky
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  Regulation of immunoglobulin E antibody synthesis in man by antiidiotypic antibodies.

Authors:  R S Geha; M Comunale
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

10.  Anti-idiotypes to monoclonal anti-H-2 antibodies. II. Expression of anti-H-2Kk idiotypes on antibodies induced by anti-idiotype or H-2Kk antigen.

Authors:  J A Bluestone; S L Epstein; K Ozato; S O Sharrow; D H Sachs
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  11 in total

Review 1.  The idiotype-antiidiotype network in human autoimmunity.

Authors:  N I Abdou
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

2.  Use of idiotype markers for cellular detection of monoclonal rheumatoid factor.

Authors:  C G Winearls; J G Sissons
Journal:  Springer Semin Immunopathol       Date:  1988

Review 3.  Phenotypic and functional analysis of lymphocytes in myasthenia gravis.

Authors:  A I Levinson; R P Lisak; B Zweiman; M Kornstein
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Anti-idiotypic antibody production in hepatitis B vaccine recipients.

Authors:  K Kobayashi; Y Ueno; H Suzuki; M Miura; R Nagatomi; M Ishii; T Toyota
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

5.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Binding specificity of antiidiotypic autoantibodies to anti-DNA antibodies in humans.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; H Saito; K Yoshinaga
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Demonstration of anti-idiotypic antibodies directed against IgM rheumatoid factor in the serum of rheumatoid arthritis patients.

Authors:  W K Hancock; E V Barnett
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

8.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

9.  Selective elimination of anti-DNA antibody-producing cells by antiidiotypic antibody conjugated with neocarzinostatin.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; Y Ono; Y Koide; N Ishida; K Yoshinaga
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Suppression of anti-DNA antibody synthesis in vitro by a cross-reactive antiidiotypic antibody.

Authors:  A Epstein; M Greenberg; B Diamond; A I Grayzel
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.